Related references
Note: Only part of the references are listed.Positron Emission Tomography/Computed Tomography Identification of Clear Cell Renal Cell Carcinoma: Results From the REDECT Trial
Chaitanya R. Divgi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Multimodal Imaging and Detection Strategy With 124 I-Labeled Chimeric Monoclonal Antibody cG250 for Accurate Localization and Confirmation of Extent of Disease During Laparoscopic and Open Surgical Resection of Clear Cell Renal Cell Carcinoma
Stephen P. Povoski et al.
SURGICAL INNOVATION (2013)
Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database
John Caddell Dickson et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
Dosimetric Analysis of 177Lu-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on 111In-cG250 Imaging
Alexander B. Stillebroer et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
Bone Marrow Dosimetry Using 124I-PET
Jazmin Schwartz et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma
Hsin-Yi Wang et al.
CANCER IMAGING (2012)
Correlation of In Vivo and In Vitro Measures of Carbonic Anhydrase IX Antigen Expression in Renal Masses Using Antibody 124I-cG250
Daniel A. Pryma et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini et al.
LANCET (2011)
Carbonic Anhydrase IX Expression in Renal Neoplasms Correlation With Tumor Type and Grade
Elizabeth M. Genega et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2010)
Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma Final Results and Analysis of Prognostic Factors
Robert J. Motzer et al.
CANCER (2010)
Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial
Martin E. Gore et al.
LANCET (2010)
Epidemiology and risk factors for kidney cancer
Wong-Ho Chow et al.
NATURE REVIEWS UROLOGY (2010)
The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases
Ingrid M. E. Desar et al.
ACTA ONCOLOGICA (2009)
Tyrosine Kinase Inhibitors - A Review on Pharmacology, Metabolism and Side Effects
Joerg Thomas Hartmann et al.
CURRENT DRUG METABOLISM (2009)
C-11-Acetate PET imaging for renal cell carcinoma
Nobuyuki Oyama et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)
Diagnostic accuracy of computed tomography-guided percutaneous biopsy of renal masses
Joery Schmidbauer et al.
EUROPEAN UROLOGY (2008)
Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma
Jean-Jacques Patard et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Contemporary Results of Percutaneous Biopsy of 100 Small Renal Masses: A Single Center Experience
Alessandro Volpe et al.
JOURNAL OF UROLOGY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma
Bradley C. Leibovich et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma
Johanna Sandlund et al.
BJU INTERNATIONAL (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (I-124-cG250) and PET in patients with renal masses: a phase I trial
Chaitanya R. Divgi et al.
LANCET ONCOLOGY (2007)
Fluorine-18 fluorothymidine: A new positron emission radioisotope for renal tumors
Nathan Lawrentschuk et al.
CLINICAL NUCLEAR MEDICINE (2006)
Radioimmunotheapy with [131I]cG250 in patients with metastasized renal cell cancer:: Dosimetric analysis and immunologic response
AH Brouwers et al.
CLINICAL CANCER RESEARCH (2005)
Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma
AH Brouwers et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography
N Lawrentschuk et al.
BJU INTERNATIONAL (2005)
Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer
M Atkins et al.
CLINICAL CANCER RESEARCH (2005)
PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats
A Brouwers et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2004)
A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients
I Bleumer et al.
BRITISH JOURNAL OF CANCER (2004)
Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma
LI Gordon et al.
CLINICAL LYMPHOMA (2004)
Prognostic value of carbonic anhydrase IX and Ki67 as predictors of survival for renal clear cell carcinoma
MHT Bui et al.
JOURNAL OF UROLOGY (2004)
Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease
NK Janzen et al.
UROLOGIC CLINICS OF NORTH AMERICA (2003)
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia:: a phase II multicenter trial
GA Wiseman et al.
BLOOD (2002)
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
I-131-cG250 monoclonal antibody immunoscintigraphy versus [F-18]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study
AH Brouwers et al.
NUCLEAR MEDICINE COMMUNICATIONS (2002)
Systemic therapy for renal cell carcinoma
RJ Motzer et al.
JOURNAL OF UROLOGY (2000)
Share Paper
